{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:24:12Z","timestamp":1757618652925,"version":"3.44.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00393-025-01678-0","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T07:41:48Z","timestamp":1752219708000},"page":"448-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Klonale Erkrankungen im Grenzbereich Rheumatologie\/H\u00e4matologie","Clonal diseases in the border zone rheumatology\/hematology"],"prefix":"10.1007","volume":"84","author":[{"given":"Markus","family":"Munder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"1678_CR1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","volume":"24","author":"SDM Cordas Dos","year":"2024","unstructured":"Cordas Dos\u00a0SDM, Toenges\u00a0R, Bertamini\u00a0L et\u00a0al (2024) New horizons in our understanding of precursor multiple myeloma and early interception. Nat Rev Cancer 24:867\u2013886","journal-title":"Nat Rev Cancer"},{"key":"1678_CR2","unstructured":"(2023) https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/monoklonale-gammopathie-unklarer-signifikanz-mgus\/@@guideline\/html\/index.html"},{"key":"1678_CR3","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2665-9913(21)00348-9","volume":"4","author":"A Marinkovic","year":"2022","unstructured":"Marinkovic\u00a0A et\u00a0al (2022) Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know. Lancet Rheumatol 4:e362\u2013e373","journal-title":"Lancet Rheumatol"},{"key":"1678_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/1055-9965.EPI-13-0695","volume":"23","author":"M McShane","year":"2014","unstructured":"McShane\u00a0M, Murray\u00a0LJ, Landgren\u00a0O et\u00a0al (2014) Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A\u00a0Systematic Review. Cancer Epidemiol Biomarkers Prev 23:332\u2013334","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1678_CR5","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1038\/leu.2016.43","volume":"30","author":"K Hemminiki","year":"2016","unstructured":"Hemminiki\u00a0K, F\u00f6rsti\u00a0A, Sundquist\u00a0K et\u00a0al (2016) Familial associations of monoclonal gammopathy of unknown significance with autoimmune diseases. Leukemia 30:1766\u20131769","journal-title":"Leukemia"},{"key":"1678_CR6","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/bloodadvances.2020003193","volume":"5","author":"N Steiner","year":"2021","unstructured":"Steiner\u00a0N, Gobel\u00a0G, Michaeler\u00a0D et\u00a0al (2021) Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma. Blood Adv 5:1746\u20131754","journal-title":"Blood Adv"},{"key":"1678_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4065\/84.8.685","volume":"84","author":"JP Bida","year":"2009","unstructured":"Bida\u00a0JP, Kyle\u00a0RA, Therneau\u00a0TM et\u00a0al (2009) Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A\u00a0Population-Based Study of 17,398 Patients. Mayo Clin Proc 84:685\u2013693","journal-title":"Mayo Clin Proc"},{"key":"1678_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.7326\/M23-2867","volume":"177","author":"I Sverrisdottir","year":"2024","unstructured":"Sverrisdottir\u00a0I, Thorsteinsdottir\u00a0S, Rognvaldsson\u00a0S et\u00a0al (2024) Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance. Ann Intern Med 177:711\u2013718","journal-title":"Ann Intern Med"},{"key":"1678_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini\u00a0G, Dispenzieri\u00a0A, Sanchorawala\u00a0V et\u00a0al (2018) Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers 4:38","journal-title":"Nat Rev Dis Primers"},{"key":"1678_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaut.2012.01.010","volume":"39","author":"P Brito-Zer\u00f3n","year":"2012","unstructured":"Brito-Zer\u00f3n\u00a0P, Retamozo\u00a0S, Gand\u00eda\u00a0M et\u00a0al (2012) Monoclonal gammopathy related to Sj\u00f6gren syndrome: A\u00a0key marker of disease prognosis and outcomes. J\u00a0Autoimmun 39:43\u201348","journal-title":"J Autoimmun"},{"key":"1678_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/jha2.964","volume":"5","author":"C Michel","year":"2024","unstructured":"Michel\u00a0C, Fehr\u00a0EM, Nolte\u00a0H et\u00a0al (2024) Effective treatment of refractory monoclonal gammopathy-associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone. EJHaem 5:838\u2013841","journal-title":"EJHaem"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01678-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01678-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01678-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:03:44Z","timestamp":1757221424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01678-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1678"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01678-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"13 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Munder gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}